Overview

An Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia Gravis

Status:
Terminated

Trial end date:
2020-12-09

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the long-term safety and tolerability of M281 in participants with generalized myasthenia gravis (gMG)

Phase:

Phase 2

Details

Lead Sponsor:

Momenta Pharmaceuticals, Inc.